Overview
Clinical trials have shown that combining the drug ribociclib with hormone therapy in the first line significantly extends the lives of patients with certain types of metastatic breast cancer. However, the people who participate in these trials do not always reflect the diversity of patients seen in everyday practice, particularly African American women and those from lower socioeconomic backgrounds. Because these groups often face greater barriers to care and poorer health outcomes, it is important to confirm that these advanced treatments are equally effective for them in the real world.
Researchers used Flatiron Health’s US Breast Cancer Panoramic Database, inclusive of more than 985,000 patients with breast cancer, to analyze the records of over 5,600 women, focusing specifically on African American patients and those living in lower-income areas. The study compared the outcomes of those who received the ribociclib combination versus those who received hormone therapy alone. The results were striking: African American patients on the combination therapy experienced an additional 19.4 months of sustained disease control and an additional 14.3 months without needing chemotherapy. Significant benefits were also observed among patients living in lower-income areas.
Why this matters
This research provides powerful evidence that the survival benefits of ribociclib extend to historically under-represented populations who often face the greatest health disparities. By demonstrating that this treatment is highly effective for these specific groups in a real-world setting, the study underscores the need to ensure equitable access to the most effective therapies. Ultimately, these findings help clinicians make better treatment recommendations and support policies aimed at closing the gap in cancer outcomes for all patients.